No­var­tis’ sim­pli­fied strat­e­gy takes shape as the com­pa­ny seeks for­mer Bris­tol My­ers CEO as chair

No­var­tis ap­pears head­ed in the right di­rec­tion now that San­doz has been spun out, op­er­a­tions have been stream­lined and the Swiss com­pa­ny is re­port­ing high­er-than-ex­pect­ed sales for sev­er­al med­i­cines.

Next up is a new board chair, po­ten­tial­ly for­mer Bris­tol My­ers Squibb CEO Gio­van­ni Caforio if share­hold­ers ac­cept his nom­i­na­tion.

The phar­ma’s stock $NVS was up about 3% on Tues­day af­ter the com­pa­ny raised its out­look for the year. That’s a “sig­nif­i­cant pos­i­tive sur­prise” in No­var­tis’ first-quar­ter up­date, Jef­feries an­a­lyst Pe­ter Welford wrote in a note. At the end of last week, the stock was down about 7% for the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER